Endocrinology Today—February 17, 2026

LucidQuest

4 hours ago

This is a week’s Endocrinology update covers research-driven disease biology insights, real-world data signals, market and access developments, and device or platform partnerships shaping care pathways.

In Today’s Newsletter

Dive deeper

🦴 Planned bone therapy after denosumab in AI-treated early breast cancer [06 Feb 2026]

https://www.osteoporosis.foundation/news/treatment-strategies-after-denosumab-discontinuation-non-metastatic-breast-cancer-treated-ai
Context: IOF cites a narrative review in Osteoporosis International on women with non-metastatic, hormone receptor–positive breast cancer treated with aromatase inhibitors (AIs) who received denosumab for bone protection.
Key point: IOF warns denosumab effects can reverse rapidly after stopping, with a “rebound phenomenon” and reports of spontaneous, sometimes multiple vertebral fractures (optimal follow-on regimen not defined).
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Visceral fat-resident macrophages as a type 2 diabetes drug target [13 Feb 2026]

https://www.insideprecisionmedicine.com/topics/translational-research/visceral-fat-resident-macrophages-identified-as-new-drug-target-for-type-2-diabetes/
Context: University of Pittsburgh work described as published in Nature Communications, using mouse obesity models and human visceral fat tissue analyses (n not stated in this source).
Key point: Researchers report a resident macrophage subset in visceral adipose tissue (VAT) that supports insulin sensitivity, with SerpinB2 linked to mitochondrial function and macrophage survival (human therapeutic impact not established).
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💉 Natco Pharma to launch generic semaglutide injection in India (March) [India • 14 Feb 2026]

https://www.ndtvprofit.com/business/natco-pharma-to-launch-diabetes-weight-loss-drug-semaglutide-in-india-in-march-11002346
Context: NDTV Profit reports Natco Pharma received a CDSCO nod to manufacture and market generic semaglutide injection, positioned for type 2 diabetes and chronic weight management.
Key point: Natco said it will launch in March and plans to out-license to two other companies (commercial terms not detailed).
Implication: Introduces competition that may affect pricing and formulary access.

📈 LifeScan partners with i-SENS to launch OneTouch Vita CGM in Europe [EU • 14 Feb 2026]

https://www.pharmabiz.com/NewsDetails.aspx?aid=184227&sid=2
Context: LifeScan (glucose monitoring) and i-SENS (IVD diagnostics) announced a partnership combining OneTouch branding and distribution with i-SENS CGM technology and manufacturing.
Key point: Companies expect a OneTouch Vita CGM launch in Germany, Ireland, Portugal, and Belgium by early 2027, with broader expansion later.
Implication: May expand screening, initiation, and follow-up at scale.

🧩 Insulet expands Omnipod 5 in the Middle East, updates NXP supply terms [Middle East • 15 Feb 2026]

https://finviz.com/news/311308/insulet-corporation-podd-announces-strategic-expansion-and-supply-agreement-update
Context: Source summarizes Insulet updates on Omnipod 5 availability and supply chain arrangements for device components via NXP USA.
Key point: Omnipod 5 is stated as commercially available in UAE, Saudi Arabia, Qatar, and Kuwait, and Insulet disclosed an addendum extending a long-term supply arrangement with amended pricing and volume terms (details not specified).
Implication: May expand screening, initiation, and follow-up at scale.

🩹 Mitochondrial circular RNA tied to diabetic wound repair [12 Feb 2026]

https://news.ki.se/mitochondrial-rna-may-contribute-to-improved-wound-healing-in-diabetes
Context: Karolinska Institutet reports a study in Advanced Science using patient tissue plus experimental wound models in human skin and mice (n not stated here).
Key point: circMTRNR2 was reported reduced in long-standing diabetic foot ulcer tissue, and raising or lowering it changed healing speed in model systems (clinical delivery method not established).
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧫 Avant Technologies rebrands to Avaí Bio, highlights diabetes cell-therapy focus [11 Feb 2026]

https://www.marketwatch.com/press-release/cnw-avant-technologies-completes-rebranding-with-name-change-to-avai-bio-and-launch-of-new-website-babee01f
Context: Company press release via MarketWatch describes a corporate name change and refreshed positioning around genetically modified cellular platforms and encapsulation.
Key point: Avant Technologies said it is now Avaí Bio and outlined programs for insulin-secreting engineered cell lines (type 1 and insulin-dependent type 2 diabetes) and an α-Klotho platform (development stage not specified).
Implication: Signals pipeline investment and modality expansion.

🧴 Bone-Viva nutraceutical study claims BMD stabilization (press release) [US • 11 Feb 2026]

https://www.prnewswire.com/news-releases/new-research-published-in-the-european-journal-of-medicine-shows-promising-results-for-women-with-osteoporosis-and-osteopenia-302684652.html
Context: AARDS press release describes an 18-month clinic study in women 50+ with osteopenia or osteoporosis, comparing Bone-Viva, denosumab, romosozumab, and combination approaches.
Key point: Release claims Bone-Viva was well tolerated and associated with stable or improved BMD, with combination therapy reported as “best” (study design and independent validation details limited in the release).
Implication: May influence prescriber choice and payer reviews pending full data.

🫁 GLP-1s associated with fewer asthma exacerbations in non-diabetic patients (TriNetX cohort) [US • 15 Feb 2026]

https://www.prnewswire.com/news-releases/glp-1s-associated-with-reduced-asthma-exacerbation-in-patients-without-diabetes-302687344.html
Context: AAAAI press release describes an observational cohort study using TriNetX data with propensity-matched overweight and obese non-diabetic asthma patients over three years.
Key point: GLP-1 initiation was associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese cohorts (causality not established).
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why it matters

Denosumab stop planning is becoming a survivorship issue in AI-treated breast cancer, with rebound fracture risk driving sequencing conversations (IOF review) [1].
Multiple biology-led angles are pushing beyond weight loss in metabolic disease, including immune-cell and mitochondrial targets (Pitt, Karolinska) [2], [6].
Semaglutide access and competition signals are spreading across regions, with India a near-term focus in these sources [3].
CGM and automated insulin delivery ecosystems continue to expand geographically and via partnerships (LifeScan–i-SENS, Insulet) [4], [5].
Observational datasets are increasingly used to suggest cross-indication effects for GLP-1s, but causality remains uncertain without prospective trials [9].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What is the IOF’s main warning on denosumab discontinuation in AI-treated early breast cancer?

Stopping denosumab can trigger rapid bone turnover and bone loss, with reported spontaneous vertebral fractures. IOF emphasizes planning a sequential strategy, often involving bisphosphonates (optimal regimen not defined). [1]

What did the University of Pittsburgh group propose as a therapeutic lever for type 2 diabetes?

They highlight visceral adipose tissue resident macrophages and SerpinB2-linked mitochondrial antioxidant capacity as a pathway tied to insulin sensitivity in models, and they mention interest in small molecules that raise SerpinB2 (preclinical). [2]

What exactly did Natco Pharma say about semaglutide in India?

Natco said it received CDSCO approval for generic semaglutide injection and plans to launch in March, with intent to out-license to two companies (additional details not provided in the article). [3]

When and where is LifeScan’s OneTouch Vita CGM expected to launch?

LifeScan and i-SENS expect initial launches in Germany, Ireland, Portugal, and Belgium by early 2027, then expand over time. [4]

What is circMTRNR2 and why does it matter for diabetic foot ulcers?

Karolinska reports circMTRNR2 is reduced in long-standing diabetic foot ulcer tissue, and modulating it affected healing speed in experimental human tissue and mouse models (clinical delivery approach not yet established). [6]

Are GLP-1s proven to reduce asthma exacerbations in people without diabetes?

The AAAAI release reports an association in a TriNetX propensity-matched cohort over three years. This is observational, so it does not establish causality. [9]

Entities / Keywords

International Osteoporosis Foundation (IOF), Osteoporosis International, denosumab, bisphosphonates, aromatase inhibitors (AI), vertebral fractures, breast cancer survivorship
University of Pittsburgh, visceral adipose tissue (VAT) macrophages, SerpinB2, insulin resistance, type 2 diabetes, Nature Communications
Natco Pharma, CDSCO, semaglutide, GLP-1 receptor agonist, Ozempic, Wegovy, Rybelsus, India generics
LifeScan, i-SENS, OneTouch Vita, continuous glucose monitoring (CGM), Germany, Ireland, Portugal, Belgium
Insulet, Omnipod 5, automated insulin delivery (AID), NXP USA, UAE, Saudi Arabia, Qatar, Kuwait
Karolinska Institutet, circMTRNR2, mitochondrial circular RNA, diabetic foot ulcer, Advanced Science
Avaí Bio (formerly Avant Technologies), encapsulation, genetically modified cell therapy, insulin-secreting cell lines, α-Klotho
Bone-Viva, AARDS, nutraceutical, osteopenia, osteoporosis, DEXA, T-score
AAAAI, TriNetX, asthma exacerbations, obesity, GLP-1 initiation